Voyager Therapeutics (VYGR) Receivables (2022 - 2026)
Voyager Therapeutics (VYGR) posted Receivables of $1.6 million for Q1 2026, down 13.96% sequentially from $1.9 million in Q4 2025, and down 22.04% YoY from $2.1 million in Q1 2025.
Voyager Therapeutics (VYGR) Receivables (2022 - 2026) Analysis & Trends
Voyager Therapeutics has reported Receivables for 5 years, with the latest figure at $1.6 million in Q1 2026.
- Quarterly Receivables fell 22.04% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 22.04% YoY) and the FY2025 annual result came in at $2.0 million, down 10.5% from the prior year.
- Receivables fell to $1.6 million in Q1 2026 per VYGR's latest filing, from $1.9 million in the prior quarter.
- Over five years, Receivables peaked at $83.5 million in Q4 2023 and troughed at $1.6 million in Q1 2026.
- A 5-year average of $13.3 million and a median of $3.4 million in 2024 frame the typical range for Receivables.
- The sharpest annual moves came in 2024 and 2025: Receivables slumped 97.39% in 2024, then retreated 12.29% in 2025.
- Over 5 years, Receivables stood at $10.2 million in 2022, then surged by 716.54% to $83.5 million in 2023, then plunged by 97.39% to $2.2 million in 2024, then declined by 12.29% to $1.9 million in 2025, then dropped by 13.96% to $1.6 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $1.6 million, $1.9 million, and $4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 912.74 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 215.33 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.09 Bn |
| 10 | Voyager Therapeutics | 201.32 Mn | 84.98 Mn | - | 3.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.15 Mn |
| Mar 31, 2026 | 1.65 Mn |
| Dec 31, 2025 | 1.91 Mn |
| Sep 30, 2025 | 4.04 Mn |
| Jun 30, 2025 | 2.53 Mn |
| Mar 31, 2025 | 2.11 Mn |
| Dec 31, 2024 | 2.18 Mn |
| Sep 30, 2024 | 19.67 Mn |
| Jun 30, 2024 | 3.25 Mn |
| Mar 31, 2024 | 3.46 Mn |
| Dec 31, 2023 | 83.49 Mn |
| Mar 31, 2023 | 25.33 Mn |
| Sep 30, 2022 | 10.23 Mn |